TrialClinical trials (London, England)2021

Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.

Elisabeth M Schaffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.